Clinical Trial Update: Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sunitinib in patients with relapsed or refractory esophageal or gastroesophageal junction cancer; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Tony Bekaii-Saab | Conditions: Esophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-03-21